IE
ALLO icon

Israel Englander’s Allogene Therapeutics ALLO Stock Holding History

Israel Englander’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-90,000
Closed -$2.27M – 5858
2020
Q4 		$2.27M Buy
+90,000
New +$2.93M ﹤0.01% 3138
2019
Q4 		– Sell
-100,000
Closed -$2.73M – 4165
2019
Q3 		$2.73M Buy
+100,000
New +$2.85M ﹤0.01% 2233

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Israel Englander's ALLO Position: Q2 2026 in Review

Israel Englander increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $3.34M and bringing the position to 4,843,889 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Israel Englander first reported a position in ALLO in Q4 2019 and has held it in 26 quarters since. The position peaked at $20.6M in Q4 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Israel Englander held 4,843,889 shares of Allogene Therapeutics worth $10.1M as of Q2 2026.
  • Israel Englander bought 1,521,836 Allogene Therapeutics shares in Q2 2026, an estimated $3.34M.
  • Allogene Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2269 holding.
  • Israel Englander first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Israel Englander's Allogene Therapeutics position peaked at $20.6M in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.